NCT05374590View on ClinicalTrials.gov

Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis

PHASE2/PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 18, 2022

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2028

Conditions
Generalized Myasthenia Gravis
Interventions
BIOLOGICAL

Efgartigimod IV or Efgartigimod PH20 SC

Intravenous infusion of Efgartigimod or Subcutaneous injection of Efgartigimod PH20 SC

Trial Locations (12)

2650

Universitair Ziekenhuis Antwerpen, Edegem

13005

AP-HM- Hôpital de La Timone, Marseille

22903

University of Virginia (UVA) Health - Developmental Pediatrics Clinic, Charlottesville

45147

Universitätsklinikum Essen, Essen

46026

Hospital Universitari i Politecnic La Fe de Valencia, Valencia

60611

Ann and Robert H Lurie Children's Hospital of Chicago - Main Hospital, Chicago

2333 ZA

Leids Universitair Medisch Centrum, Leiden

80-211

Uniwersyteckie Centrum Kliniczne w Gdansku, Gdansk

40-123

Wielospecjalistyczna Poradnia Lekarska Synapsis, Katowice

02-097

Centralny Szpital Kliniczny - Uniwersyteckie Centrum Kliniczne WUM, Warsaw

WC1N 3JH

Great Ormand Street Hospital for Children NHS Foundation Trust - Great Ormond Street Hospital - Pediatric Neurology, London

OX3 9DU

Oxford University Hospitals NHS Foundation Trust - John Radcliffe Hospital Children's Hospital, Oxford

Sponsors

Lead Sponsor

argenx
All Listed Sponsors
lead

argenx

INDUSTRY

NCT05374590 - Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis | Biotech Hunter | Biotech Hunter